Title : Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature.

Pub. Date : 2020 Jul 4

PMID : 32622356






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 After biopsy confirmation, patient was initially started on gemcitabine and oxaliplatin combination followed by gene sequencing, which showed Tp53 (exon 7-c.713 G > A and exon 5-c.376-2A > G) and EGFR (exon 20-T790M) mutation, and erlotinib was added to chemotherapy, after 6 cycles of chemotherapy patient showed a 90% partial radiological response as per RECIST criteria. Oxaliplatin tumor protein p53 Homo sapiens